Ekran Resmi 2016-09-19 16.10.14

Publication Biography

 

  • Sayar N., Ozturk R., Karahan G., Konu O*, Yulug IG*. Meta-Analysis of epigenetic reactivation by 5-AZA treatment in different cancers. (In preparation).
  • Bozdogan O., Vargel I., Cavusoglu T., Karabulut AA, Karahan G., Sayar N. , Atasoy P., and Yulug IG*. “Metastatic Suppressor Proteins in Cutaneous Squamous Cell Carcinoma”, Pathology Research and Practice. Accepted in December 3, 2015.
  • Sayar N., Karahan G., Konu O., Bozkurt B., Bozdogan O., Yulug I.G.*, “Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer” Clinical Epigenetics, 7:104, 2015.
  • Oztemur , Bekmez T, Aydos A., Yulug IG, Bozkurt B, Gur-Dedeoglu B, “A ranking-based meta-analysis reveals let-7 miRNAs as a meta-signature for grade classification in breast cancer”, PLosOne. DOI:10.1371/journal.pone.0126837, May 15, 2015.
  • Karahan G., Sayar N., Gozum G., Konu O., Yulug IG*, “Relative expression of rRNA species and 45S rDNA promoter methylation status are dysregulated in tumors in comparison with adjacent normals in breast cancer”. Oncology Reports. 33: 3131-3145, 2015.
  • Bozdogan O, Yulug IG*, Vargel I, Çavuşoğlu T, Karabulut AA, Karahan G, Sayar “Differential Expression Patterns of Metastasis Suppressor Proteins in Basal Cell Carcinoma”, International Journal of Dermatology, 54: 905-915, 2015.
  • Camcı MT, Sayar N., Yulug IG, Suzer S., “Zn Prolongs the Stability of Antibacterial Silver-Copper Nanoalloys” Biophysics and Biochemistry (BAB), Volume 1 Issue 4, December 2013.
  • Taner M, Sayar N., Yulug IG, Suzer S., “Synthesis, characterization and antibacterial investigation of silver-copper nanoalloys”, Journal of Material Science, 21(35), 13150-13154, 2011.
  • Gur-Dedeoglu B., Konu O., Yulug I G., “Identification of endogenous reference genes for qRT-PCR analysis in normal matched breast tumor tissues”. Oncology Research, 17 (8), 353-365, 2009. DOI:3727/096504009788428460.
  • Canbay E., Gür-Dedeoglu B., Bozkurt B., Karabeyoglu M., Ünal B., Yıldırım O., Cengiz O., Yulug I G. “Inhibition of focal adhesion kinase with her-2 targeted antibody pertuzumab (Omnitarg, 2C4) in breast cancer”. Gene Therapy and Molecular Biology, Vol 12, 293- 300, (2008).
  • Gur-Dedeoglu B., Konu O., Kir S., Ozturk R A., Bozkurt B., Seckin S., Yulug I G. “A Resampling Based Meta-Analysis for Detection of Differential Gene Expression in Breast Cancer”. BMC Cancer, 8:396, doi:10.1186/1471-2407-8-396, 2008.
  • Isik G. Yulug and Bala Gur-Dedeoglu “Functional Genomics in Translational Cancer Research: Focus on Breast Cancer”. Briefings in Functional Genomics and Proteomics. doi:10.1093/bfgp/eln009 (2008).
  • Petenkaya A., Bozkurt B., Akilli-Ozturk O., Kaya HS., Gur-Dedeoglu B., Yulug I.G. “Lack of Association Between the MDM2 – SNP309 Polymorphism and Breast Cancer Risk” Anticancer Research 29: 4975-4978 (2006).
  • Ozturk N., Erdal E., Mumcuoglu M., Akcali K.C., Yalcin O., Senturk, S., Ergul A., Gur B., Yulug I., Cetin-Atalay R., Yakicier C., Yagci T., Tez M., Ozturk M. “Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells” Proceedings of the National Academy of Sciences 103 (7): 2178-2183, (2006).
  • Turk M., Dincer S., Yulug I.G., Biskin E. “In vitro tansfection of HeLa cells with temperature sensitive polycationic copolymers”. Journal of Controlled Release 96: 325-340 (2004).
  • Sevinc A., Yannoukakos D., Konstantopoulou I., Manguloglu E., Luleci G., Colak T., Akyerli C., Colakoglu G., Tez M., Sayek I., Gerassimos V., Nasioulas G., Papadopoulou E., Florentin L., Kontogianni E., Bozkurt B., Kocabas N. A., Karakaya A.E., Yulug I.G., Ozcelik T. “Lack of Association Between RNASEL Arg462Gln Variant and the Risk of Breast Cancer”. Anticancer Research 24: 2547-2549 (2004).
  • Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., Yulug I.*, Merlano M., Numico G., Comino A., Attard M., Reelfs O., Gusterson B., Bell A.K., Heath V., Tavassoli M., Farrell P.J., Smith P., Lu , Crook T. “p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis”. Cancer Cell 3: 387-402 (2003). (* Equal contribution).
  • Gasco M., Yulug I.G., Crook T. “p53 mutations in familial breast cancer: functional aspects” Human Mutation 21(3): 301-6 (2003).
  • Atalay A., Crook T., Ozturk M., Yulug I.G. “Identification of genes induced by BRCA1 in breast cancer cells”. Biochemical Biophyical Reserach Communication Dec 20;299(5): 839-46 (2002).
  • Gasco M., Bell AK., Heath V., Sullivan A., Smith P., Hiller L., Yulug I., Numico G., Merlano M., Farrell P.J., Tavassoli M, Gusterson B., Crook T. “Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16INK4a silencing and human Papillomavirus negativity “. Cancer Research 62: 2072-2076 (2002).
  • Sullivan A., Yuille M., Repellin C., Reddy A., Reelfs O., Bell A., Dunne B., Gusterson B.A., Osin P., Farrell P.J., Yulug I., Evans A., Ozcelik T., Gasco M., Crook T. “Concomitant inactivation of p53 and Chk2 in breast cancer” Oncogene 21(9): 1316-1324 (2002).
  • Marin M.C., Jost A.J., Brooks L.A., Irwin M.S., O’Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G., Vousden K.H., Allday M.J., Gusterson B., Ikawa S., Hinds P.W., Crook T., Kaelin Jr W.G.. “A common polymorphism acts as an intragenic modifier of mutant p53 behaviour”. Nature Genetics 25: 47-54 (2000).
  • Crook T., Brooks L.A., Crossland S., Osin P., Baker K., Waller J., Philip E., Smith P., Yulug I.G., Peto J., Parker G., Allday M.J.,Crompton M.R., Gusterson B.A. “p53 mutations with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumors”. Oncogene 17 (13): 1681-1689 (1998).
  • Hoyle J., Yulug I.G., Johnstone K., Scambler P.J., Fisher E.M.C “Characterisation of a short interspersed repeat (Mermaid) that has family members on human chromosome 21 and elsewhere in the human genome”. Human Genetics 97: 117-120 (1996).
  • Yulug I.G., Killary A. M., Athwal R. S.,Sandhu A.K., Fox M., Fisher E.M.C. “Gene expression in response to retinoic acid in novel human chromosome 21 monochromosomal cell hybrids”. Somatic Cell and Molecular Genetics 21 (5): 357-365 (1995).
  • Yulug I.G., Yulug, A., Fisher E.M.C. “The frequency and position of Alu repeats in cDNAs, as determined by database searching”. Genomics 27: 544-548 (1995).
  • Yulug I.G., See C.G., Fisher E.M.C. “The DAD1 protein, whose defect causes apoptotic cell death, maps to human chromosome 14”. Genomics 26: 433-435 (1995).
  • Yulug I.G., Egan S.E., See C.G., Fisher E.M.C. “A human SHC-related sequence maps to chromosome 17, the SHC gene maps to chromosome 1”. Human Genetics 96: 245-248 (1995).
  • Yulug I.G., Katsanis N., De Belleroch J., Collinge J., Fisher E.M.C. “An improved protocol for the analysis of SOD1 gene mutations, and a new mutation in Exon 4”. Human Molecular Genetics 4 (6): 1101-1104 (1995).
  • Yulug I.G., Hillerman R., Fisher E.M.C. “The SHB adaptor protein maps to human chromosome 9”. Genomics 24: 615-617 (1994).
  • Hoyle J., Yulug I.G., Egan S.E., Fisher E.M.C. “The gene that encodes the phosphatidylinositol-3 kinase regulatory subunit (p85a) maps to chromosome 13 in mouse”. Genomics 24: 400-402 (1994).
  • Hernandez D., Egan S.E., Yulug I.G., Fisher E.M.C. “Mapping the gene that encodes phosphatidylinositol-specific phospholipase C- g-2 in the human and the mouse”. Genomics 23: 504-507 (1994).
  • Yulug I.G., Egan S.E., See C.G., Fisher E.M.C. “Mapping GRB2, a signal transduction gene in the human and the mouse”. Genomics 22: 313-318 (1994).
  • Yulug I.G., Egan S.E., Pollock P.M., Fisher E.M.C. “A homologue of the Drosophila Son of Sevenless gene maps to mouse chromosome 17”. Genomics 18: 733-734 (1993).
  • Gulpinar Yulug I., Piskin A.K . “Kinetics of normal human erythrocyte insulin receptors”. Hacettepe Medical Journal 23(2): 127-134 (1992).
  • Gülpınar Yulug I., Kart A., “The Structure of Eukaryotik Genome”. The Turkish Journal of Cancer 20 (1): 5-15 (1990).